Канада - Енглески - Health Canada

pharmascience inc - sulfasalazine - tablet - 500mg - sulfasalazine 500mg - sulfonamides

Канада - Енглески - Health Canada

pharmascience inc - sulfasalazine - tablet (enteric-coated) - 500mg - sulfasalazine 500mg - sulfonamides

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - azulfidine en-tabs tablets are indicated: azulfidine en-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, azulfidine en-tabs does not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of azulfidine en-tabs is apparent. azulfidine en-tabs tablets are contraindicated in: hypersensitivity to sulfasalazine, its metabolites, sulfonam

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - azulfidine tablets are indicated: azulfidine tablets are contraindicated in: none reported.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Израел - Енглески - Ministry of Health

takeda israel ltd - idursulfase - concentrate for solution for infusion - idursulfase 2 mg/ml - idursulfase - idursulfase - long term treatment of patients with hunter syndrome (mps ii).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - idursulfase (unii: 5w8jgg2651) (idursulfase - unii:5w8jgg2651) - idursulfase 6 mg in 3 ml - elaprase is indicated for patients with hunter syndrome (mucopolysaccharidosis ii, mps ii). elaprase has been shown to improve walking capacity in patients 5 years and older. in patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older. the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age [see use in specific populations (8.4)]. none. risk summary there are no adequate and well-controlled studies with elaprase use in pregnant women. available data from a small number of postmarketing cases with elaprase use in pregnancy are insufficient to inform drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no evidence of adverse effects on pre- and post-natal development wa

Панама - Енглески - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

wallace pharmaceuticals pvt. ltd. - sulfasalazina - sulfasalazina....500.000 mg.

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - sulfasalazine - tablets gastro-resistant - 500mg

Канада - Енглески - Health Canada

apotex inc - sulfasalazine - tablet - 500mg - sulfasalazine 500mg - sulfonamides